Bispecific CAR-iNKT cells: beyond dual antigen targeting
Abstract
Comment on : Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A. Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia. Blood. 2026 Jan 8;147(2):180-196. doi: 10.1182/blood.2025029302. PMID: 40898981; PMCID: PMC12824662.
Fields of Study & Subjects
Immune Cell Function and Interaction
CAR-T cell therapy research
Phagocytosis and Immune Regulation
Publication details
- Journal / source
- Blood
- Volume
- 147
- Issue
- 2
- Pages
- 100–101
- Publication date
- 8 January 2026
- Language
- EN